LBRXLB Pharmaceuticals Inc

1. Sep 15, 2026Appointment of Chief Medical Officer On September 15, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Susan G. Kozauer, M.D. has been appointed to serve as the Company’s Chief Medical Officer, effective as of September 14, 2026 (the “Start Date”)Director or officer change · Form 8-K
2. Sep 3, 2026Appointment of Chief Financial Officer On September 3, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Joseph M. Miller has been appointed to serve as the Company’s Chief Financial Officer, effective as of September 2, 2026 (the “Start Date”)Director or officer change · Form 8-K
3. Aug 11, 2026LB Pharmaceuticals Reports Second.Earnings release · press release
4. Jul 29, 2026On July 28, 2026, LB Pharmaceuticals Inc (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of (i) …Material agreement entered · Form 8-K
5. Jul 22, 2026On July 22, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing accelerated timing of topline results from the Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia.Other event · Form 8-K
6. Jun 10, 2026On June 16, 2026, Anna Eramo, M.D., for personal reasons will transition to a role of advisor to LB Pharmaceuticals Inc (the “Company”). On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the “Separation Date”)Director or officer change · Form 8-K
7. May 12, 2026LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
8. Mar 26, 2026LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate.Earnings release · press release
9. Mar 16, 2026Departure of Director On March 13, 2026, Zachary Prensky notified the Board of Directors (the “Board”) of LB Pharmaceuticals Inc (the “Company”) of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”)Director or officer change · Form 8-K
10. Mar 10, 2026Appointment of Director On March 6, 2026, the Board of Directors (the “Board”) of LB Pharmaceuticals Inc (the “Company”) appointed Robert A. Lenz, to the Board, effectively immediately.Director or officer change · Form 8-K
11. Feb 5, 2026On February 4, 2026, LB Pharmaceuticals Inc (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of (i) …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.